🔗 Share this article

An underground economy for unlicensed weight-loss drugs is being driven by social media fitness personalities and sellers on messaging platforms, according to recent findings.

Experimental Drug Acquiring Traction Online

The experimental drug, which remains in research studies, is being advertised by online personalities for its alleged weight-reducing effects. Followers are urged to message these accounts directly for supplier links, while also receiving promotional offers.

Active Commerce on Social Networks

Separately, a flourishing market exists on Telegram, where communities with numerous of participants share comparison photos, injection guides and claims of rapid British shipping. Sellers promote the substance there before redirecting customers to other platforms for purchases.

Learning About Retatrutide

Retatrutide is an investigational injectable developed by American pharmaceutical company Eli Lilly. The treatment affects three intestinal hormones – GLP-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies indicate it could assist patients reduce up to a quarter of their total weight. Referred to as the “triple G”, the drug is being hailed digitally as the successor to Ozempic.

Healthcare Professionals Voice Worries

However, physicians and chemists have warned that the sale of what is still an unlicensed medication in the United Kingdom is a cause for concern and could lead to users administering substances of uncertain source.

Several professionals stated the popularity for retatrutide could be linked to the rising cost of approved slimming treatments such as Mounjaro.

Regulatory Position and Implementation

Marketing the unapproved drug on social media or Telegram is prohibited in the UK, as it is an unlicensed medication that cannot be promoted or distributed for human use under the British medical regulations.

Several influencers attempt to circumvent the rules by referring to the substance as a “research chemical” or describing it as “not for human consumption”. The substance is not a restricted drug, but advertising and distribution can still violate medicines, marketing, and consumer laws, risking penalties, legal action or imprisonment.

Service Reaction and Material Elimination

Based on the social media company, the service has taken down problematic material and banned related keywords and query recommendations. The company stated it was committed to keeping the service safe and investing in enhancing compliance measures.

Digital Trading Activities

Research also found groups with up to nine thousand participants marketing retatrutide using the platform's integrated search feature, which operates like a online catalog. Typing “retatrutide” immediately brings up groups with thousands of members, populated with images of weight loss, glowing testimonials and detailed instructions for mixing or administering at home.

After moments of joining one community, a seller shared WhatsApp details, where most purchases take place. The seller sent an instruction manual and guaranteed delivery within 48 hours. When questioned whether the product was authentic, one vendor responded: “You can’t be sure.” Another shared a photo of a supposed laboratory certificate. None inquired about weight, medical conditions or previous experience.

Product Information and Costs

Within these groups, posts display black plastic parcels with postal service labels, stating to include new batches. One communication stated: “It took eight of us to load them this morning.”

Customers can select between powder vials, mixed at home with sterile water, or ready-to-use pens usually priced at £160 for 20mg. When asked how long a injector should be used, sellers give contradictory answers varying between a few weeks to “depends on your body”.

Platform Oversight and Safety Measures

A spokesperson for the messaging service said it actively monitored harmful content on its platform including content that promoted the “misuse of controlled medications”. The company added that it removed “millions of pieces of harmful content each day”.

Healthcare Expert Warnings

“People are administering materials they cannot confirm. Although the science behind this drug is valid, these digital versions may not include what they advertise,” said a pharmacy expert, the head of pharmacy at Chemist4U.

A medical professional of an online medical service linked the increase in demand to recent price rises for approved weight-loss medications such as Mounjaro. “With prices rising, individuals are turning to online platforms. But counterfeit injections are highly dangerous. You cannot know what’s contained or whether the conditions they were made in was clean,” she explained.

Her team has already seen individuals injured by personal administration from unconfirmed suppliers. “We understand the disappointment, but buying from messaging apps or communication platforms is taking chances with your well-being,” stated the doctor. “These substances could be contaminated or improperly measured.”

Manufacturer Statement

A representative from Eli Lilly stated retatrutide was in phase 3 clinical trials and had not been evaluated or approved by any government authority globally. “Therefore at this point no one can sell [it] for human use,” they explained, adding that any item “falsely representing itself as a company investigational substance not yet approved … may subject patients to potentially significant medical dangers”.